



Dear valued healthcare professional,

We are navigating through a truly unprecedented time as we face the escalation of COVID-19 and, as a society, collectively take efforts to reduce the impact of the virus. For GBT, the health and safety of the sickle cell community and of our employees are our highest priority. As we work to address the current pandemic, I want to convey GBT's commitment to you and the patients we serve.

GBT supports and is aligned with public health strategies designed to stem the spread of COVID-19, including social distancing and other methods. These steps are critical to slowing the trajectory of the illness and reducing the risk to patients, clinic staff and our employees.

As a result, we are suspending our in-person interactions with healthcare professionals until April 7, 2020, at which time we will reevaluate the situation. In the meantime, we will continue to provide and scale up digital and internet-based education and outreach, and our non-personal promotion activities, such as our speakers' bureau and disease awareness campaign, will continue on a virtual basis.

Additionally, GBT Source, our support program for those prescribed Oxbryta® (voxelotor) tablets, is fully functional and remains available to support you and your patients. We continue to be available to assist with new enrollments, reimbursement, financial and copay support, and adherence and refill support. Also, we believe we currently have sufficient supply of Oxbryta to sustain patient need through the remainder of the year and into 2021.

Despite this challenging, rapidly changing time, I can assure you that GBT is acutely focused on our mission to transform the treatment and care of people living with sickle cell disease. We appreciate that, while we are taking measures to reduce the risk of spreading the virus, our nation's healthcare professionals are on the front lines, continuing to provide quality care to our most vulnerable populations. We thank you deeply for your commitment.

Should you require GBT's assistance, you can reach us at [message.tedlove@gbt.com](mailto:message.tedlove@gbt.com), or please don't hesitate to contact your Sickle Cell Therapeutic Specialist, who will be following up with your clinic on a routine basis.

Sincerely,

A handwritten signature in black ink, appearing to read "Ted W. Love". The signature is fluid and cursive, with a large initial "T" and "L".

Ted W. Love, M.D.  
President and CEO  
Global Blood Therapeutics